Bildkälla: Stockfoto

Xbrane Biopharma: BLA re-submission delayed to Q1 2023 - Redeye

Redeye leaves its comments on Xbrane following today's news that the re-submission to the FDA has been delayed from Q4 2022 to Q1 2023. We adjust our model and fair value range for the minor delay.

Redeye leaves its comments on Xbrane following today's news that the re-submission to the FDA has been delayed from Q4 2022 to Q1 2023. We adjust our model and fair value range for the minor delay.
Börsvärldens nyhetsbrev
ANNONSER